These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27272783)

  • 1. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
    Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
    Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinases: from biology to pathology.
    Choura M; Rebaï A
    J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
    Zarei O; Benvenuti S; Ustun-Alkan F; Hamzeh-Mivehroud M; Dastmalchi S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2429-2446. PubMed ID: 27503093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
    Fan Y; Arechederra M; Richelme S; Daian F; Novello C; Calderaro J; Di Tommaso L; Morcrette G; Rebouissou S; Donadon M; Morenghi E; Zucman-Rossi J; Roncalli M; Dono R; Maina F
    Hepatology; 2017 Nov; 66(5):1644-1661. PubMed ID: 28586114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM; Foran JM; Fiedler W; Serve H; Paquette RL; Cooper MA; Yuen HA; Louie SG; Kim H; Nicholas S; Heinrich MC; Berdel WE; Bello C; Jacobs M; Scigalla P; Manning WC; Kelsey S; Cherrington JM
    Clin Cancer Res; 2003 Nov; 9(15):5465-76. PubMed ID: 14654525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types.
    Grillo E; Ravelli C; Corsini M; Gaudenzi C; Zammataro L; Mitola S
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166313. PubMed ID: 34826586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
    Keppler S; Weiβbach S; Langer C; Knop S; Pischimarov J; Kull M; Stühmer T; Steinbrunn T; Bargou R; Einsele H; Rosenwald A; Leich E
    Oncotarget; 2016 Jun; 7(25):38762-38774. PubMed ID: 27246973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase receptors as attractive targets of cancer therapy.
    Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.